secwatch.observer — SEC 8-K summary
======================================

Issuer:     Quoin Pharmaceuticals, Ltd. (QNRX)
CIK:        0001671502
Form:       8-K
Filed at:   2023-08-02T23:59:59+00:00
Accession:  0001104659-23-086860
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Quoin posts Q2 net loss $2.1M, reports positive clinical data for first Netherton Syndrome subject
--------------------------------------------------------------------------------

- Cash, equivalents and securities at June 30, 2023: ~$15.4M; runway extends into 2H 2024.
- Net loss Q2 2023: ~$2.1M vs ~$2.7M in Q2 2022; first-half 2023 loss ~$4.7M.
- First subject in open-label Netherton Syndrome study showed fully clear skin at QRX003 treatment sites and substantial pruritis improvement.
- Majority of patients across both Netherton Syndrome studies expected to be enrolled by end of August 2023.
- Regained Nasdaq minimum bid price compliance; closing bid price at $1.00+ for 10 consecutive days.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1671502/000110465923086860/0001104659-23-086860-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1671502/000110465923086860/tm2322693d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-086860

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer